LEO Pharma Showcases New Real-World Data on Tralokinumab at AAD 2026, Highlighting Benefits Across Diverse Atopic Dermatitis Populations LEO Pharma has presented new post-hoc analyses from its ongoing TRACE study, offering important real-world insights into the effectiveness of tralokinumab in…
Biocytogen Enters Platform Licensing Agreement with Taisho to Expand Use of RenNano® Antibody Discovery Technology Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a global biotechnology company recognized for its innovation in antibody-based drug discovery, has announced a new strategic collaboration with Taisho…
Incyte Reports Positive 54-Week Late-Breaking Povorcitinib Data in Hidradenitis Suppurativa at AAD 2026 Incyte has reported new long-term findings from its pivotal Phase 3 STOP-HS clinical development program, highlighting the sustained safety and efficacy of povorcitinib (INCB54707), an investigational oral,…
Eli Lilly and Company Reports Up to Four Years of Sustained Disease Control with EBGLYSS (lebrikizumab-lbkz) in Moderate-to-Severe Atopic Dermatitis Eli Lilly and Company has unveiled compelling new long-term data demonstrating that its biologic therapy EBGLYSS (lebrikizumab-lbkz) can deliver sustained…
Real Time Medical Systems to Showcase How Live Data Enhances Clinical Standards and Survey Readiness at PALTC26 Real Time Medical Systems, widely recognized as a leading provider of post-acute care analytics and a KLAS-rated, HITRUST-certified solution, has announced its expanded…
Banner|Aetna Engages Community at the 2026 Phoenix Heart Walk Banner|Aetna, an integrated health plan formed through a collaboration between Banner Health and CVS Health through its Aetna business, is actively participating in the 2026 Phoenix Heart Walk, taking place on…
Allergan Aesthetics Introduces Next-Generation Hyaluronic Acid Injectables with JUVÉDERM at AMWC Monaco Allergan Aesthetics, an AbbVie company, a global leader in medical aesthetics treatments and manufacturers of the market-leading JUVÉDERM® Collection of Fillers,3,4,‖ is once again forging ahead and has announced that…
Drug Farm Secures U.S. FDA Orphan Drug Designation for DF-003 in Treating ROSAH Syndrome Drug Farm has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its investigational therapy DF-003, a small molecule…
Aledade Partners Demonstrate Superior Hypertension Control, Surpassing Large Health Systems in New Case Study Aledade, a physician-led organization recognized as a national leader in advancing value-based care, has released the findings of a new case study highlighting the effectiveness of…
Long Bridge Medical Secures U.S. Food and Drug Administration Clearance to Launch Pivotal U.S. Study of LensOne Prosthetic Capsular Bag Long Bridge Medical, Inc. has reached an important regulatory milestone with the clearance from the U.S. Food and Drug Administration…
Aerin Medical Achieves Milestone of Treating Over 200,000 Patients with Its Minimally Invasive Therapies for Chronic Nasal Disorders Aerin Medical Inc., a recognized innovator in minimally invasive therapies for chronic nasal conditions, has announced a major milestone in its clinical…
Imperative Care Launches CLEAR-IT Clinical Study to Advance Standards in Peripheral Thromboembolism Treatment Imperative Care Inc has announced a significant milestone in its efforts to advance treatment options for patients with thromboembolic diseases, marking the enrollment of the first patient…